Topic: REDUCE-AMI Trial Speaker: Birju Rao, MD Topic: An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease Speaker: Graham Smith, MD
Пікірлер: 1
@daviddobies2993Ай бұрын
A critical appraisal of the quality of the trials is needed. Bempedoic acid did not have an effect on secondary prevention. This was not discussed in the NEJM article. Data sharing needs to be done or the results should not be published. Also BMJ article regarding Repatha demonstrated that the CRF didn’t match the results. Data sharing is required.